How Roche Combines Diagnostics and Pharmaceuticals in Its Work

Updated

Roche describes its business as combining "life-changing diagnostics and medicines" to take on the healthcare challenges that place the greatest strain on patients, families, communities, and health systems. The company frames this as a three-part mission—prevent, stop, and cure—with diagnostics and pharmaceuticals each playing a distinct role at every stage. The logic is sequential: diagnostics identify who is at risk and what is wrong, and medicines act on that information.

The three-part mission and what each part relies on

Roche's own description of its mission in action breaks the work into three stages, each tied to a specific capability.

Stage What Roche says it does Capability it depends on
Prevent Identify high-risk patients early so medicines can be used in time Diagnostics
Stop Accurately diagnose patients and deliver targeted medicines to halt disease progression Diagnostics plus pharmaceuticals
Cure Identify the cause of a patient's condition and restore health through curative medicines Pharmaceuticals, informed by diagnosis

The pattern is that diagnostics carry the "prevent" stage almost entirely, while "stop" and "cure" require the two sides to work together. A targeted medicine only makes sense once a diagnosis has established what to target.

Why the combination matters more than either part alone

The company's stated rationale is that combining the two strengths lets it "provide real and positive change for patients, the people they love, and the professionals who care for them." The emphasis on patients, families, and care professionals as separate audiences is a signal about where the value is expected to land: earlier identification (fewer patients arriving too late), more precise treatment (less trial-and-error for clinicians), and slower disease progression (less burden on families and health systems).

Roche also states that it is "guided by the experiences of patients" in deciding what to prevent, stop, and cure—positioning patient experience as an input to prioritization rather than only an outcome.

What this looks like in practice

Roche's published material includes examples that show the diagnostics-plus-pharma model at work rather than only describing it.

  • Multiple sclerosis. A Roche article discusses why "targeting relapsing and progressive biology is important in multiple sclerosis," and describes crossing the blood-brain barrier to target chronic inflammation in order to help prevent disability progression. This is a case where understanding the disease mechanism (a diagnostic and scientific question) and intervening on it (a pharmaceutical question) are treated as one problem.
  • Sequencing by expansion (SBX). Roche describes SBX as "a sensitive new sequencing method," presented in the context of diagnostics and laboratory readiness as "where health security begins." This illustrates the diagnostics side operating at the level of public health infrastructure, not just individual patient testing.
  • Pipeline ambition. CEO Thomas Schinecker states that the company now aims "to bring up to 20 new medicines to patients by 2030," and that this quarter brought "meaningful progress in areas where patients urgently need better treatment options." The stated target is about medicines, but the selection of those areas depends on diagnostic identification of unmet need.

How to read Roche's claims critically

If you are evaluating Roche as a company, an employer, or a partner, a few distinctions help.

  • Stated mission versus reported results. The mission language ("prevent, stop and cure") is aspirational framing. The verifiable figures Roche publishes are financial and operational—for example, sales of CHF 30.4 billion by HY 2026, a 6% (CER) sales increase in the first nine months of 2026, and a dividend yield of 3.2% for FY 2025. These measure commercial performance, not health outcomes.
  • "Combined strengths" is a strategic claim, not a guarantee. The integration of diagnostics and pharmaceuticals is Roche's stated differentiator, but the site does not quantify how much of its pipeline depends on paired diagnostic tests. Treat the integration as a described strategy rather than a measured one.
  • Time horizon. The 2030 medicines target and the next scheduled report (28 January 2027) are the concrete checkpoints Roche itself names. Use those dates to assess whether the stated progress materializes.

For a general orientation, the site's "We are Roche" and "Our mission in action" sections are the primary sources for how the company defines itself; the Investor center and Media center hold the figures and announcements that let you test those definitions against results.